[1] EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017, 67:145-172.
[2] Castro RE, Rodrigues CMP. Cell Death and microRNAs in Cholestatic Liver Diseases: Update on Potential Therapeutic Applications. Current Drug Targets, 2017, 18:921-931.
[3] Ananthanarayanan M, Banales JM, Guerra MT, et al. Post-translational regulation of the type III inositol 1,4,5-trisphosphate receptor by miRNA-506. J Biol Chem, 2015, 290:184-196.
[4] Erice O, Munoz-Garrido P, Vaquero J, et al. MiRNA-506 promotes primary biliary cholangitis-like features in cholangiocytes and immune activation. Hepatology, 2017.
[5] Castro RE, Ferreira DM, Afonso MB, et al. miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol, 2013, 58:119-125. |
